By the mean of a validated immunoenzymatic assay, the levels of α-syn heterocomplexes were quantified: HC presented comparable RBC concentrations of α-syn-tau with respect to PD subjects, while a highly significant enhancement of α-syn-Aβ1–42 species was found in pathological RBCs. Here, MAPT is linked to Parkinson disease.